for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Danaher Corporation

DHR

Latest Trade

216.78USD

Change

-0.44(-0.20%)

Volume

1,407,208

Today's Range

215.01

 - 

218.54

52 Week Range

119.60

 - 

248.32

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
217.22
Open
218.20
Volume
1,407,208
3M AVG Volume
51.00
Today's High
218.54
Today's Low
215.01
52 Week High
248.32
52 Week Low
119.60
Shares Out (MIL)
710.38
Market Cap (MIL)
153,995.60
Forward P/E
35.99
Dividend (Yield %)
0.33

Next Event

Danaher Corp at Evercore ISI HealthCONx Conference (Virtual)

Latest Developments

More

Danaher Reports Third Quarter Earnings Per Share $1.16

HHS Says Trump Administration Expands Manufacturing Capacity With Cytiva For Components Of Covid-19 Vaccines

FDA Emergency Use Authorization Awarded To Beckman Coulter Access IL-6 Test

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Danaher Corporation

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through three segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification. Danaher's research and development, manufacturing, sales, distribution, service and administrative facilities were located in over 60 countries.

Industry

Scientific & Technical Instr.

Contact Info

2200 Pennsylvania Ave NW Ste 800w

WASHINGTON, DC

20037-1731

United States

+1.202.8280850

https://www.danaher.com/

Executive Leadership

Steven M. Rales

Chairman of the Board

Rainer M. Blair

President, Chief Executive Officer, Director

Matthew R. McGrew

Chief Financial Officer, Executive Vice President

Daniel L. Comas

Executive Vice President

Joakim Weidemanis

Executive Vice President

Key Stats

1.75 mean rating - 20 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

18.3K

2018

19.9K

2019

17.9K

2020(E)

22.0K
EPS (USD)

2017

4.030

2018

4.520

2019

4.420

2020(E)

6.026
Price To Earnings (TTM)
52.15
Price To Sales (TTM)
8.39
Price To Book (MRQ)
4.44
Price To Cash Flow (TTM)
34.58
Total Debt To Equity (MRQ)
57.50
LT Debt To Equity (MRQ)
57.44
Return on Investment (TTM)
5.09
Return on Equity (TTM)
4.61

Latest News

Latest News

U.S. government signs deal to make more COVID-19 vaccine components

The U.S. government has entered an agreement with life sciences company Cytiva, a unit of Danaher Corp, to expand the manufacturing of products needed to make COVID-19 vaccines, the U.S. Department of Health and Human Services (HHS) said on Tuesday.

U.S. govt signs deal to make more COVID-19 vaccine components

The U.S. government has entered an agreement with Danaher Corp-owned Cytiva to expand the manufacturing of products that are essential for producing COVID-19 vaccines, the U.S. Department of Health and Human Services said on Tuesday.

KKR hires ex-Danaher executive for industrial deals

Private equity firm KKR & Co Inc <KKR.N> said on Monday it had hired former Danaher Corp <DHR.N> executive Dan Daniel to bolster its team that focuses on acquiring and operating industrial businesses in the United States.

U.S. FDA allows emergency use of Danaher's COVID-19 antibody test

Medical device maker Danaher Corp said on Monday its COVID-19 blood test for detecting if a person had ever been infected with the new coronavirus received emergency use clearance from the U.S. Food and Drug Administration.

BRIEF-Danaher Says Entered Into New $2.5 Billion 364-Day Revolving Credit Facility

* DANAHER CORP - ON JUNE 5, 2020, ENTERED INTO NEW $2.5 BILLION 364-DAY REVOLVING CREDIT FACILITY

BRIEF-Danaher Announces Pricing Of Common Stock, Mandatory Convertible Preferred Stock Offering

* DANAHER ANNOUNCES PRICING OF COMMON STOCK OFFERING AND MANDATORY CONVERTIBLE PREFERRED STOCK OFFERING

BRIEF-Danaher Announces Offerings Of Common Stock And Mandatory Convertible Preferred Stock

* DANAHER ANNOUNCES OFFERINGS OF COMMON STOCK AND MANDATORY CONVERTIBLE PREFERRED STOCK

BRIEF-Danaher Corporation Announces CEO Transition

* DANAHER CORP - RAINER M. BLAIR TO SUCCEED THOMAS P. JOYCE, JR. AS PRESIDENT AND CEO IN SEPTEMBER 2020

BRIEF-Danaher Reports Q1 Adjusted Non-GAAP Earnings Per Share $1.05

* Q1 REVENUE $4.3 BILLION VERSUS REFINITIV IBES ESTIMATE OF $4.29 BILLION

BRIEF-Danaher Announces Quarterly Dividend Of $0.18 Per Share

* SETS REGULAR QUARTERLY CASH DIVIDEND OF $0.18 PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Sartorius Stedim Biotech Completes Acquisition Of Selected Assets Of Danaher's Life Sciences Portfolio

* COMPLETES ACQUISITION OF SELECTED ASSETS OF DANAHER'S LIFE SCIENCES PORTFOLIO

BRIEF-Danaher Anticipates Positive Results In Each Of Three Reporting Segments In Q1

* DANAHER PROVIDES UPDATE ON FIRST QUARTER 2020 FINANCIAL PERFORMANCE AND SCHEDULES FIRST QUARTER EARNINGS CONFERENCE CALL

BRIEF-Danaher Says Priced A Reopening Of EUR 150 Mln Of Additional 1.700% Senior Notes Due 2024 At An Offering Price Of 100.298%

* DANAHER CORP - PRICED A REOPENING OF EUR 150 MILLION OF ADDITIONAL 1.700% SENIOR NOTES DUE 2024 AT AN OFFERING PRICE OF 100.298%

BRIEF-Danaher Completes Acquisition Of GE's Biopharma Unit

* DANAHER COMPLETES ACQUISITION OF THE BIOPHARMA BUSINESS OF GENERAL ELECTRIC LIFE SCIENCES; BUSINESS WILL BE CALLED CYTIVA Source text for Eikon: Further company coverage:

BRIEF-GE Completes Biopharma Sale To Danaher, Receives $20 Billion Net Cash Proceeds

* GE ANNOUNCES COMPLETION OF BIOPHARMA SALE TO DANAHER, RECEIVES $20 BILLION NET CASH PROCEEDS Source text for Eikon: Further company coverage:

BRIEF-Danaher Corp Issued EUR 750 Million Of 1.700% Senior Notes Due 2024

* DANAHER CORP - ISSUED EUR 750 MILLION OF 1.700% SENIOR NOTES DUE 2024

BRIEF-Danaher Files For Offering Of €750 mln 1.700% Senior Notes Due 2024, €500 mln 2.100% Senior Notes Due 2026, €500 mln 2.500% Senior Notes Due 2030

* DANAHER CORP FILES FOR OFFERING OF €750 MILLION 1.700% SENIOR NOTES DUE 2024, €500 MILLION 2.100% SENIOR NOTES DUE 2026 - SEC FILING

BRIEF-Danaher Corp Says CEO Thomas P. Joyce, Jr.'s FY 2019 Total Compensation Was $18.2 Mln

* DANAHER CORP SAYS CEO THOMAS P. JOYCE, JR.'S FY 2019 TOTAL COMPENSATION WAS $18.2 MILLION VERSUS $15.4 MILLION IN 2018 - SEC FILING

BRIEF-Danaher Corp Files Prelim Prospectus Supplement Related To Senior Notes Offering

* DANAHER CORP FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO 3-PART EURO-DENOMINATED SENIOR NOTES OFFERING; SIZE UNDISCLOSED - SEC FILING Source text: (https://bit.ly/2UBrXAp) Further company coverage:

BRIEF-Sartorius Says European, U.S. Antitrust Authorities Clear Acquisition Of Select Danaher Life Science Businesses

* EUROPEAN AND U.S. ANTITRUST AUTHORITIES CLEAR ACQUISITION OF SELECT DANAHER LIFE SCIENCE BUSINESSES BY SARTORIUS STEDIM BIOTECH

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up